Patient characteristics
| Patient/Sex . | Age . | Onseta . | Disease Duration (years) . | Drugsb . |
|---|---|---|---|---|
| 1/F | 21 | poly+ | 9.0 | NSAIDs |
| 2/F | 18 | poly− | 15.0 | NSAIDs |
| 3/F | 16 | poly+ | 8.0 | NSAIDs |
| 4/F | 15 | poly− | 12.0 | NSAIDs, Gold |
| 5/M | 14 | poly+ | 0.5 | NSAIDs, MTX, HCLq |
| 6/F | 15 | poly+ | 0.75 | NSAIDs, MTX, HCLq |
| 7/M | 14 | systemic | 2.0 | NSAIDs, MTX, HCLq |
| 8/F | 13 | poly+ | 4.0 | NSAIDs |
| 9/F | 12 | pauci | 10.0 | NSAIDs |
| 10/F | 07 | poly− | 0.75 | NSAIDs |
| 11/F | 06 | poly− | 0.83 | NSAIDs |
| 12/F | 05 | poly− | 1.17 | NSAIDs |
| 13/F | 21 | poly+ | 16 | NSAIDs, Gold |
| 14/F | 18 | poly+ | 5 | NSAIDs, MTX, HCLq |
| 15/F | 02 | pauci | 0.5 | NSAIDs |
| 16/F | 7.5 | pauci | 5.5 | NSAIDs |
| 17/F | 5.5 | pauci | 4.0 | NSAIDs |
| Patient/Sex . | Age . | Onseta . | Disease Duration (years) . | Drugsb . |
|---|---|---|---|---|
| 1/F | 21 | poly+ | 9.0 | NSAIDs |
| 2/F | 18 | poly− | 15.0 | NSAIDs |
| 3/F | 16 | poly+ | 8.0 | NSAIDs |
| 4/F | 15 | poly− | 12.0 | NSAIDs, Gold |
| 5/M | 14 | poly+ | 0.5 | NSAIDs, MTX, HCLq |
| 6/F | 15 | poly+ | 0.75 | NSAIDs, MTX, HCLq |
| 7/M | 14 | systemic | 2.0 | NSAIDs, MTX, HCLq |
| 8/F | 13 | poly+ | 4.0 | NSAIDs |
| 9/F | 12 | pauci | 10.0 | NSAIDs |
| 10/F | 07 | poly− | 0.75 | NSAIDs |
| 11/F | 06 | poly− | 0.83 | NSAIDs |
| 12/F | 05 | poly− | 1.17 | NSAIDs |
| 13/F | 21 | poly+ | 16 | NSAIDs, Gold |
| 14/F | 18 | poly+ | 5 | NSAIDs, MTX, HCLq |
| 15/F | 02 | pauci | 0.5 | NSAIDs |
| 16/F | 7.5 | pauci | 5.5 | NSAIDs |
| 17/F | 5.5 | pauci | 4.0 | NSAIDs |
poly−, polyarticular seronegative JRA; poly+, polyarticular seropositive JRA; pauci, pauciarticular JRA.
NSAID, nonsteroidal antiinflammatory drug; MTX, methotrexate; HCLq, hydroxychloroquine.